FDA places recall on Medtronic guidewires

Candace Stuart | | Cardiovascular Business | Interventional Cardiology

The FDA issued a Class I recall on Medtronic guidewires used in PCIs and in the placement of left ventricular leads for cardiac rhythm devices.

Minneapolis-based Medtronic is notifying hospitals and distributors that the coating on the surface of some models of guidewires may delaminate and detach. The company said it received some complaints, including one that involved patient injury. It advised customers to quarantine the recalled guidewires and return them to the company for replacement or credit.

The affected guidewires were manufactured after mid-April 2013 under the following product lines:

  • Cougar nitinol workhorse guidewire
  • Cougar steerable guidewire
  • Zinger stainless steel workhorse guidewire
  • Zinger steerable guidewire
  • Thunder extra-support guidewire
  • Thunder steerable guidewire
  • ProVia crossing guidewire
  • Attain Hybrid guidewire

Candace Stuart, Contributor

Related Content

Surgery outperforms PCI in NSTEMI patients with multivessel CAD
Boston Scientific enters IVL arms race with acquisition worth up to $664M
FDA sees value in no-implant heart failure device
Radial secondary access during TAVR limits complications
Medtronic’s Harmony TPVR system gains CE mark approval
History made: Young child treated with new heart device for very first time

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.